Non Bacterial Cystitis including Interstitial Cystitis

Dr G. Testa

Paper given at 12th National Conference of the Continence Foundation of Australia Dec 4 2003 Manly Pacific Hotel

Definition

- Catchterm that comprises a variety of medical disorders
 - Nonbacterial infectious (viral, mycobacterial, chlamydial & fungal)
 - Noninfectious (radiation, drug induced, autoimmune)
 - Interstitial cystitis
- All have common symptoms
 - Urgency, frequency, dysuria
 - Occasionally, hematuria, dyspareunia, abdominal cramps and or bladder pain and spasms

Frequency

Nonbacterial Infectious
 HSV 1 & 2
 Adenovirus
 BK Polyoma virus
 Chlamydia
 Mycobacterium Tuberculosis
 Fungal

Frequency

Noninfectious cystitis

- Radiation
- Drug Induced
 - Chemotherapy
 - Cyclophosphamide
 - Low dose methotrexate
 - Tiaprofenic Acid (Surgam)

- Autoimmune

- Sjogren syndrome
- Systemic lupus erythematosus

Etiology

Infectious

- May have acute, subacute or chronic course
- Viral or Mycobacterial cystits
 - Can involve other organ systems
 - May depend on the degree of host immunosuppression
- Fungal occur in immunocompromised

Noninfectious

- Radiation Volume, dose & delivery technique
- SLE & Sjogrens are said to resemble an interstitial cystits like picture
- Cyclophosphamide: Metabolite acrolein
- Tiaprofenic acid: Mechanism unknown

Clinical

Infectious

- Symptoms include urgency, frequency & dysuria and occasionally may include hematuria, dyspareunia, abdominal cramps and /or bladder pain and spasm
- HSV wide range of symptoms
- Chlamydia may have associated mucopurulent cervical or urethral discharge

Noninfectious

- Radiation Cystitis Grade 1-3
- SLE & Sjogrens present mainly as frequency & suprapuic pain
- Chemical Cystitis Acute & fulminant but more often delayed and mild

History

History of Symptoms
 General medical history

 Diabetes, arthritis, atopic states, autoimmune diseases
 History of medical treatments for malignancy
 Drug history- including chronic antibiotic therapy

 Specific medical history

 Sexual history
 Travel, immigration etc

Workup

Infectious

- Viral infections often difficult to diagnose PCR
- Chlamydia PCR
- Tuberculosis Prior exposure Mantoux test, Tissue staining, or PCR
- Fungal microscopy of wet smears or histological sections, culture on media, PCR

Noninfectious

- Radiation Obtain relevant history, MSU or cystoscopy
- Autoimmune detection of ANA,
 - SLE: anti-(ds) DNA, anti-(Sm) & anti-RNP
 - Sjogrens: Schirmer tear test, anti-Ro, anti-La & lacrimal biopsy

Imaging Studies

Possible imaging tests include ultrasound, CT, IVP or MRI

Management

Infectious

- HSV 2
- Acyclovir (Acyclo-V) 400 mg tds 10 days
- Valaciclovir (Valtrex) 1000 mg tds 7 days
- Adenovirus
 - Ganciclovir (Cymevene) protocol related
- Chlamydia
 - Doxycycline (Doryx) 100 mg bd for 7 days
 - Azithromycin (Zithromax) 1 gm single oral dose
 - Erythromycin 500 mg QID for 7 days
- Mycobacterium
 - Generally begins with 3-4 agents and varied due to drug sensitivities

Fungal

- ♦ If in immunocomprimised with IDC \rightarrow remove IDC
- Oral azole antifungal agent Ketoconazole (Nizoral) 200mg daily 2-4 weeks
- Bladder irrigations amphotericin B 50 mcg/ml for 5 days
- Consider IV amphotericin B in seriously ill immunosuppressed with disseminated fungal infection

Management

Noninfectious

- Radiation
 - Minor bleeding generally self limiting
 - Severe bleeding requires hospitalisation
 - Cystoscopy + clot evacuation +/- diathermy
 - Multitude of other interventions bladder irrigations of various chemicals
 - Ultimately Urinary diversion
- Chemical
 - Cease Drug
 - Hydration
 - Mesna- synthetic suphydryl compound binds acrolein
 - Aggressive hydration with IV fluids + diuretic
- Autoimmune
 - Combination of symptomatic relief, anti-inflamatory & immunosuppressive therapy

Interstitial Cystitis

Etiology

Infection
Leaky urothelium
Immunologic
Neurogenic inflammation
Pelvic floor hyperactivity
Abnormalities of Vanilloid receptors

Pathology


 Pathologic diagnosis one of exclusion with no specific or clear criteria

 No specific or diagnostic light microscopic pathologic features by either routine histopathology or immunohistochemistry
 Electron Microscopy has provided new observations

NIDDK Inclusion Griterion

•Glomerulations or Hunner's ulcer on cystoscopic examination, and





•Pain associated with the bladder or urinary urgency

NIDDK Exclusion Criterion

Bladder capacity >350 mL on awake cystometry using either gas or liquid as filling medium

- Absence of intense urge to void with bladder filled to 100 mL of gas or 150 mL of water during cystometry, using a fill rate of 30-100 mL/min
- **Demonstration of phasic involuntary bladder contractions during cystometry using fill rate described above**
- **Duration of symptoms less than 9 months and age <18**
- Absence of nocturia

4

5.

- 6. Symptoms relieved by antimicrobials, urinary antiseptics, anticholinergics, or antispasmodics (muscle relaxants)
- 7. Frequency of urination while awake <8 times per day

NIDDK Exclusion Criterion

- **B. Diagnosis of bacterial cystitis or prostatitis within 3 month period**
- 9. Bladder or lower ureteral calculi
- **10.** Active genital herpes
- **11.** Uterine, cervical, vaginal, or urethral cancer
- 12. Urethral diverticulum
- **13.** Cyclophosphamide or any type of chemical cystitis
- **14. Tuberculous cystitis**

Current Management of Interstitial Cystitis

Conservative therapy

Diet

- 53-63% can identify acidic fluids or foods incite flair
 - Mechanisms for this poorly understood not due to decreased urinary Ph from ingestion (Fisher et al)
- Foods high in arylalkylamines
 - ♦ Mechanism tryptophan metabolites → Disruption of GAG layer (Kaufman et al)
- Special diet remains a reasonable first line therapy for patients with irritative voiding symptoms
- Tolerable food for IC patients include:-
 - Rice, pasta, potatoes, vegetables, chicken, meat, watermelons and grapefruit

Current Management of Interstitial Cystitis

Conservative therapy

Behavioural therapy

- 50 75% reduction of symptoms in 50% of patient
- Bladder training with deferment techniques \rightarrow increase intervoid intervals

Treatment of Pelvic Floor Dysfunction

- Lilius reported 81 % of his IC Patients to have spasm & tenderness of the levator ani musculature
- Use of trans-rectal Thiele massage, biofeedback & electrogalvanic stimulation

Management – Oral Therapies

<u>DRUG</u>	MODE OF ACTION	<u>RESULTS</u>
Pentosan Polysulphate	GAG replacement	28-32% improvement
Amitriptyline	Anticholinergic, Sedation & Inhibition of Serotonin & NAD reuptake	64-90% response Decrease frequency , nocturia & pain
Hydroxyzine	H1 receptor antagonist \rightarrow inhibits mast cell activation	30-55% response – effective in atopic individuals
Gabapentin	Unknown	50-63% response – mainly pain relief
Nifedapine	Calcium channel blocker	Up to 75% response – ½ relapse after 4 months
Nalmefiene	Opioid antagonist → Inhibits mast cell degranuation	Up to 59% response
L-Arginine	Substrate for nitric oxide synthase	Up to 33% response
Oxybutynin	Acetylcholine inhibitor	Adjuvant therapy
Tolteridine	Muscarinic receptor antagonist	Adjuvant therapy
Oxycodone	Short acting narcotic	Used to relieve pain while other therapies taking effect
Suplatast Tosilate	Immunoregulatory Drug	71% complete response 14% partial response lasting 1 year

Management – Intravesical Therapies

<u>YasredT</u>	Mode of Action	<u>Results</u>
Hydrodistention	 Ischaemia of submucosal bladder plexus Widespread mast cell content exhaustion 	 Dependant on bladder capacity under General Anaesthesia: > 600 mls 12% > 600 mls 26% No response > 6 months
DMSO	 Antiinflammatory Desensitisation / Blockade of afferent nociceptive pathways 	 93% response rate 40-52% relapse rate at 24 months 93% response to further treatment
BCG	Immune modulator	 60% response Persistent response in 89% at 27 months
Chlorpactin	Bleach like agent	50-60% response rate of 6 months duration
Hyaluronic Acid	 GAG replacement Free radical scavenging Immune modulation 	56-71% Response rate
Resiniferatoxin	Desensitization of bladder efferents	80% response but short lived
Multiagent therapy	Additive effect of individual agents	92% response rate – mean duration 8 months

Current Management of Interstitial Cystitis

Surgical Therapy

10 % disease severe enough for major surgical intervention

Surgical procedures include:

Subtrigonal or supratrigonal cystectomy and substitution cystoplasty

• Cystectomy with urinary diversion (either ileal conduit, continent diversion or neobladder

Conservative Therapy

Diet Behavioural therapy Treatment Pelvic Floor Dysfunction

Oral Therapy

Pentosan Polysulfate Hydroxyzine Amitriptyline

> Gabapentin Narcotics

Intravesical Therapy

Hydrodistention DMSO Multiagent Therapy

BCG Hyaluronic Acid Resiniferatoxin

Surgical Therapy

Sacral Neuromodulation

Cystectomy with Substitution Cystoplasty Urinary Diversion with or without Cystectomy